A P2X3 antagonist, MK-7264/AF-219, known as gefapixant, is currently being tested in various advanced clinical trials with subjects with pulmonary disease and chronic cough (NCT01432730, NCT02502097, and NCT02477709). Here, P2RX3 is linked to lung disorder.